Concepedia

Matthew L. Rizk

ML

36

Publications

1.9K

Citations

23

H-Index

2008

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

University of California San Diego

Rady Children's Hospital-San Diego

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Matthew L. Rizk is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and microbiology.

ORCID

Top concepts

Publications per year

2008–2023

36

Publications

36

Ensemble Modeling of Metabolic Networks

Linh M. Tran, Matthew L. Rizk, James C. Liao · Biophysical Journal · 2008 · 269 citations · Full text

, , +7

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov, Richard G. Wunderink, Antoine Roquilly et al. · Clinical Infectious Diseases · 2020 · 213 citations · Full text

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes et al. · The Lancet Infectious Diseases · 2011 · 190 citations

, , +7

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Christopher Lucasti, Liviu Vasile, Dorel Săndesc et al. · Antimicrobial Agents and Chemotherapy · 2016 · 177 citations · Full text

, , +22

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Matthew L. Rizk, Yaming Hang, Wen‐Lin Luo et al. · Antimicrobial Agents and Chemotherapy · 2012 · 92 citations · Full text

Rows per page

1–5 of 36